Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
60
TMDX Quote, Financials, Valuation and Earnings
Last price:
$127.00
Seasonality move
:
28.3%
Day range:
$127.51 - $130.89
52-week range:
$55.00 - $156.00
Dividend yield:
0%
P/E ratio:
51.78x
P/S ratio:
8.85x
P/B ratio:
12.33x
Volume:
384.2K
Avg. volume:
826.6K
1-year change:
104.63%
Market cap:
$4.4B
Revenue:
$441.5M
EPS (TTM):
$2.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMDX
TransMedics Group, Inc.
|
$144.8M | $0.36 | 28.37% | 94.67% | $144.73 |
|
AXGN
Axogen, Inc.
|
$56.9M | $0.07 | 17.39% | 556.06% | $35.44 |
|
ELMD
Electromed, Inc.
|
$16.6M | -- | 11.04% | -- | $36.00 |
|
IRIX
IRIDEX Corp.
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo, Inc.
|
$9.4M | -$0.11 | -13.8% | -1168.66% | $5.00 |
|
STXS
Stereotaxis, Inc.
|
$8.4M | -$0.06 | 43.22% | -30.79% | $4.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group, Inc.
|
$128.20 | $144.73 | $4.4B | 51.78x | $0.00 | 0% | 8.85x |
|
AXGN
Axogen, Inc.
|
$32.84 | $35.44 | $1.5B | -- | $0.00 | 0% | 7.28x |
|
ELMD
Electromed, Inc.
|
$27.35 | $36.00 | $228.1M | 29.42x | $0.00 | 0% | 3.65x |
|
IRIX
IRIDEX Corp.
|
$1.10 | -- | $18.9M | -- | $0.00 | 0% | 0.36x |
|
MYO
Myomo, Inc.
|
$0.91 | $5.00 | $35M | -- | $0.00 | 0% | 0.90x |
|
STXS
Stereotaxis, Inc.
|
$2.45 | $4.20 | $228.6M | -- | $0.00 | 0% | 7.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMDX
TransMedics Group, Inc.
|
59.39% | 2.406 | 13.56% | 6.86x |
|
AXGN
Axogen, Inc.
|
35.99% | -0.858 | 8.25% | 2.56x |
|
ELMD
Electromed, Inc.
|
-- | 1.217 | -- | 4.58x |
|
IRIX
IRIDEX Corp.
|
50.55% | 0.834 | 18.81% | 1.03x |
|
MYO
Myomo, Inc.
|
45.68% | -2.855 | 35.87% | 1.94x |
|
STXS
Stereotaxis, Inc.
|
32.62% | 1.831 | 1.93% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group, Inc.
|
$84.5M | $23.3M | 11.55% | 33.29% | 16.2% | $61.9M |
|
AXGN
Axogen, Inc.
|
$46M | $1.9M | -1.19% | -1.94% | 3.18% | $1.4M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
IRIX
IRIDEX Corp.
|
$4M | -$1.4M | -54.1% | -155.93% | -11.3% | -$1.2M |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
STXS
Stereotaxis, Inc.
|
$4.1M | -$5.2M | -141.59% | -218.3% | -69.75% | -$4.2M |
TransMedics Group, Inc. vs. Competitors
-
Which has Higher Returns TMDX or AXGN?
Axogen, Inc. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of 1.18%. TransMedics Group, Inc.'s return on equity of 33.29% beat Axogen, Inc.'s return on equity of -1.94%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M AXGNAxogen, Inc.76.55% $0.01 $188.7M -
What do Analysts Say About TMDX or AXGN?
TransMedics Group, Inc. has a consensus price target of $144.73, signalling upside risk potential of 12.89%. On the other hand Axogen, Inc. has an analysts' consensus of $35.44 which suggests that it could grow by 8.26%. Given that TransMedics Group, Inc. has higher upside potential than Axogen, Inc., analysts believe TransMedics Group, Inc. is more attractive than Axogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group, Inc.7 3 0 AXGNAxogen, Inc.7 0 0 -
Is TMDX or AXGN More Risky?
TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Axogen, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.241%.
-
Which is a Better Dividend Stock TMDX or AXGN?
TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Axogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or AXGN?
TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than Axogen, Inc. quarterly revenues of $60.1M. TransMedics Group, Inc.'s net income of $24.3M is higher than Axogen, Inc.'s net income of $708K. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 51.78x while Axogen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 8.85x versus 7.28x for Axogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group, Inc.8.85x 51.78x $143.8M $24.3M AXGNAxogen, Inc.7.28x -- $60.1M $708K
-
Which has Higher Returns TMDX or ELMD?
Electromed, Inc. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of 12.65%. TransMedics Group, Inc.'s return on equity of 33.29% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About TMDX or ELMD?
TransMedics Group, Inc. has a consensus price target of $144.73, signalling upside risk potential of 12.89%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 31.63%. Given that Electromed, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Electromed, Inc. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group, Inc.7 3 0 ELMDElectromed, Inc.4 0 0 -
Is TMDX or ELMD More Risky?
TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.
-
Which is a Better Dividend Stock TMDX or ELMD?
TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or ELMD?
TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. TransMedics Group, Inc.'s net income of $24.3M is higher than Electromed, Inc.'s net income of $2.1M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 51.78x while Electromed, Inc.'s PE ratio is 29.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 8.85x versus 3.65x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group, Inc.8.85x 51.78x $143.8M $24.3M ELMDElectromed, Inc.3.65x 29.42x $16.9M $2.1M
-
Which has Higher Returns TMDX or IRIX?
IRIDEX Corp. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of -12.6%. TransMedics Group, Inc.'s return on equity of 33.29% beat IRIDEX Corp.'s return on equity of -155.93%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M IRIXIRIDEX Corp.32.15% -$0.09 $9.5M -
What do Analysts Say About TMDX or IRIX?
TransMedics Group, Inc. has a consensus price target of $144.73, signalling upside risk potential of 12.89%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 81.82%. Given that IRIDEX Corp. has higher upside potential than TransMedics Group, Inc., analysts believe IRIDEX Corp. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group, Inc.7 3 0 IRIXIRIDEX Corp.0 0 0 -
Is TMDX or IRIX More Risky?
TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.
-
Which is a Better Dividend Stock TMDX or IRIX?
TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or IRIX?
TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than IRIDEX Corp. quarterly revenues of $12.5M. TransMedics Group, Inc.'s net income of $24.3M is higher than IRIDEX Corp.'s net income of -$1.6M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 51.78x while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 8.85x versus 0.36x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group, Inc.8.85x 51.78x $143.8M $24.3M IRIXIRIDEX Corp.0.36x -- $12.5M -$1.6M
-
Which has Higher Returns TMDX or MYO?
Myomo, Inc. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of -36.3%. TransMedics Group, Inc.'s return on equity of 33.29% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About TMDX or MYO?
TransMedics Group, Inc. has a consensus price target of $144.73, signalling upside risk potential of 12.89%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 449.45%. Given that Myomo, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Myomo, Inc. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group, Inc.7 3 0 MYOMyomo, Inc.4 0 0 -
Is TMDX or MYO More Risky?
TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.
-
Which is a Better Dividend Stock TMDX or MYO?
TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or MYO?
TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. TransMedics Group, Inc.'s net income of $24.3M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 51.78x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 8.85x versus 0.90x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group, Inc.8.85x 51.78x $143.8M $24.3M MYOMyomo, Inc.0.90x -- $10.1M -$3.7M
-
Which has Higher Returns TMDX or STXS?
Stereotaxis, Inc. has a net margin of 16.91% compared to TransMedics Group, Inc.'s net margin of -86.59%. TransMedics Group, Inc.'s return on equity of 33.29% beat Stereotaxis, Inc.'s return on equity of -218.3%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M STXSStereotaxis, Inc.54.94% -$0.07 $17.1M -
What do Analysts Say About TMDX or STXS?
TransMedics Group, Inc. has a consensus price target of $144.73, signalling upside risk potential of 12.89%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 71.43%. Given that Stereotaxis, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Stereotaxis, Inc. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group, Inc.7 3 0 STXSStereotaxis, Inc.3 0 0 -
Is TMDX or STXS More Risky?
TransMedics Group, Inc. has a beta of 2.061, which suggesting that the stock is 106.067% more volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.
-
Which is a Better Dividend Stock TMDX or STXS?
TransMedics Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or STXS?
TransMedics Group, Inc. quarterly revenues are $143.8M, which are larger than Stereotaxis, Inc. quarterly revenues of $7.5M. TransMedics Group, Inc.'s net income of $24.3M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, TransMedics Group, Inc.'s price-to-earnings ratio is 51.78x while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group, Inc. is 8.85x versus 7.22x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group, Inc.8.85x 51.78x $143.8M $24.3M STXSStereotaxis, Inc.7.22x -- $7.5M -$6.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
